Are Supplements Regulated? The Real Answer Is Complicated

Walk into any pharmacy and you'll see it printed on every supplement bottle: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

That disclaimer has fueled a myth: supplements exist in some regulatory Wild West, where manufacturers can make any claim and sell anything without oversight.

The reality is different.

Supplements are regulated, just not the way drugs are. If you're a brand founder trying to navigate this landscape, understanding the difference could save you from a $50,120-per-violation penalty from the FTC, or worse, a public FDA warning letter that becomes part of your company's permanent record.

Let's break down what supplement regulation looks like, starting with the law that created the modern industry.

The Dietary Supplement Health and Education Act (DSHEA) was signed by President Bill Clinton on October 25, 1994. Senator Orrin Hatch (R-Utah) and Senator Tom Harkin (D-Iowa) championed it, fundamentally reshaping how supplements are regulated in the United States.

To understand DSHEA, you need to understand what came before it.

Before DSHEA: The FDA Was Cracking Down

In 1973, the FDA issued regulations stating that vitamins and minerals with greater than 150% of the Recommended Daily Allowance potency must be classified as "drugs." Congress responded with the Proxmire Amendment of 1976, which:

• Revoked FDA's authority to set maximum limits on vitamin/mineral potency
• Prevented FDA from regulating vitamin/mineral potency for drug classification purposes
• Expanded the terms under which vitamins and minerals could be marketed

By the late 1980s and early 1990s, the FDA was pushing back. The L-tryptophan crisis, in which 38 deaths were attributed to contaminated L-tryptophan supplements, gave the agency ammunition to tighten enforcement.

The supplement industry fought back with an aggressive lobbying campaign. Senator Orrin Hatch, who received $475,637 throughout his career from the supplement industry (the most of any member of Congress), led the charge. His connections went deeper than campaign contributions.

According to 2003 financial disclosures, Hatch owned 35,621 shares of Pharmics, a Utah-based nutritional supplement company. His son Scott Hatch is a longtime industry lobbyist in Washington, as are at least five of Hatch's former aides.

The industry's lobbying power didn't end with Hatch's retirement. During the 2016 presidential election cycle alone, the supplement industry gave a record $9.7 million to build congressional support for maintaining DSHEA's post-market regulatory framework.

What DSHEA Did

DSHEA had two goals:

• Ensure continued consumer access to dietary supplements
• Provide consumers with more information about the intended use of dietary supplements

It classified supplements as a category of food, not drugs. This is the critical point. Supplements didn't suddenly become "unregulated"; they became regulated differently.

Here's how:

For drugs:

• Manufacturer must prove safety and efficacy through rigorous pre-market testing
• FDA approval required before sale

For supplements:

• FDA has limited pre-market authority
• Regulation is post-market enforcement
• Burden of proof is on the government to show a product is unsafe

The New Dietary Ingredient (NDI) Loophole

DSHEA did create one pre-market notification requirement: if you're using an ingredient that wasn't marketed in the U.S. before October 15, 1994, you must submit a New Dietary Ingredient (NDI) notification to the FDA at least 75 days before launching.

Here's the catch: this is not an approval process. The FDA receives the notification and can respond, but it cannot block market entry unless it objects within 75 days. The manufacturer only needs to provide evidence the NDI is "reasonably expected to be safe," a far lower bar than drug approval.

Structure/Function Claims: The Gray Area

Under DSHEA, supplement companies can make structure/function claims, statements about how a product affects the structure or function of the body.

For example:

• "Supports immune health" ✅
• "Maintains joint flexibility" ✅
• "Promotes cardiovascular function" ✅

These claims don't require FDA pre-approval. The manufacturer just has to:

• Notify the FDA within 30 days of marketing the product
• Include the standard DSHEA disclaimer
• Have substantiation that the claim is truthful

But you cannot make disease claims:

• "Prevents cancer" (prohibited)
• "Treats arthritis" (prohibited)
• "Cures heart disease" (prohibited)

Those require FDA approval, which means your product would be classified as a drug.

The Third Category: FDA-Approved Health Claims

There's a middle ground between structure/function claims and prohibited disease claims: FDA-approved health claims.

These claims suggest a dietary ingredient may reduce the risk of a disease or health-related condition. The distinction matters: "reduce the risk" is permissible; "prevents" is not.

Example of an approved health claim:

"Adequate calcium may reduce the risk of osteoporosis."

Notice the language: "may reduce the risk," not "prevents." This claim required FDA review and approval before use.

For most supplement brands, structure/function claims are the practical route. No FDA pre-approval required, just substantiation and the DSHEA disclaimer. But if you're formulating around a well-established nutrient-disease relationship (calcium-osteoporosis, folate-neural tube defects), FDA-approved health claims may be worth pursuing.

So if supplements don't require pre-market approval, does that mean FDA has no power? No.

Here's what the FDA can do under current law:

1. Enforce Current Good Manufacturing Practices (21 CFR Part 111)

Since 2007, supplement manufacturers have been required to follow Current Good Manufacturing Practices (cGMPs). These rules are extensive:

Component Specifications:

• Manufacturers must establish specifications for identity, purity, strength, composition, and potential contaminants
• Identity testing is mandatory for all dietary ingredients
• Relying solely on a supplier's Certificate of Analysis is insufficient

Master Manufacturing Records (MMR):

• Written records required for each unique formulation and batch size
• Comprehensive Standard Operating Procedures (SOPs) for all production steps

Batch Production Records (BPR):

• Must document equipment maintenance, cleaning, and sanitizing
• Unique identifiers for each component
• Actual yield vs. theoretical yield
• All testing results performed during batch production

Quality Control:

• Testing for contamination (yeast, mold, salmonella, E. coli, heavy metals)
• Verification that finished products meet label specifications

The most common FDA observations (violations)? Missing component and finished product specifications and failure to test raw materials for identity. These aren't obscure technical requirements. They're basic quality control measures.

2. Require Adverse Event Reporting

If a manufacturer receives a serious adverse event report related to a dietary supplement, the manufacturer must send the report to FDA as specified by law.

Between 2004 and 2016, the FDA received 56,574 adverse event reports, of which 25,412 were for dietary supplements. Reported outcomes included death, life-threatening conditions, hospitalizations, and birth defects.

3. Issue Warning Letters

FDA can issue warning letters requesting manufacturers voluntarily recall adulterated or misbranded supplements.

The volume is accelerating. Between July and December 2025, FDA issued 327 warning letters, a 73% increase over the same period in 2024. Even more telling: FDA issued 58 untitled letters in fiscal year 2025, up from just 5 in 2024 and 4 in 2023.

Untitled letters are FDA's "pre-warning" mechanism, less severe than warning letters but still official notice of violations. This spike suggests FDA is casting a wider enforcement net.

Emerging enforcement trends for 2025-2026:

• Social media enforcement: At least 5 warning letters in Q2 2025 targeted supplement brands making disease claims on TikTok and Instagram
• CBD and Delta-8: 4 warning letters related to CBD and delta-8 products marketed as dietary supplements
• Facility conditions: IsoThrive Inc. (February 2024) received a warning letter for objectionable conditions observed during FDA facility inspection

Recent examples of serious violations include:

• Pivo IV Inc. (March 2025): Dietary supplement was actually an unapproved drug
• Western Innovations, Inc. (November 2024): Adulterated dietary supplement violations, including cGMP violations
• Mihon Corp. d/b/a VitalityVita (January 2025): Products marketed as dietary supplements were unapproved new drugs

What this means for brands: If you're making health claims on social media, you're on FDA's radar. If your manufacturing facility has quality control issues, expect unannounced inspections. The enforcement perimeter is expanding rapidly.

4. Take Legal Action: Injunctions and Seizures

If a manufacturer fails to take corrective action after a warning letter, FDA can:

• Seek an injunction preventing manufacture, distribution, or sale
• Seize adulterated or misbranded products posing public health risks

However, FDA must work through the Department of Justice to seek judicial enforcement, which adds time and complexity.

5. Pursue Civil and Criminal Penalties

Consequences of non-compliance include:

• Civil money penalties: $10,000 to $1 million per violation
• Product seizures
• Import refusals
• Criminal prosecution

Here's what many brands don't realize: FDA warning letters are public, permanent records. They signal federal compliance failures to competitors, investors, and consumers. The FTC and state regulatory authorities can "piggyback" off FDA warning letters to begin their own enforcement.

Between 2007 and 2016, the FDA identified 776 adulterated dietary supplements from 146 different companies.

Recent recalls:

• StuffbyNainax LLC: Recalled MR.7 SUPER 700000 capsules, contained sildenafil and tadalafil
• One Source Nutrition: Recalled Vitality capsules, contained sildenafil and tadalafil
• Amazon Warning (December 2023): FDA lab analysis of 7 products revealed sildenafil and tadalafil

What these numbers tell us:

Sexual enhancement and weight loss products are the highest-risk categories, accounting for 86.4% of all adulteration cases. If you're launching in these categories, expect heightened FDA scrutiny.

146 companies over 10 years equals roughly 15 companies caught per year, but this represents only products FDA tested. The actual adulteration rate is likely much higher.

The adulterants are prescription drugs, not harmless fillers. Sildenafil (Viagra) and sibutramine (banned weight loss drug) create serious drug interaction risks. This isn't "mislabeling"; it's selling drugs disguised as supplements.

Supply chain implications: Most adulteration occurs at the white-label manufacturing level, not in-house. If you're working with a contract manufacturer, verify:

• Raw material identity testing protocols (don't just accept supplier COAs)
• Finished product testing for known adulterants
• Whether they manufacture sexual enhancement or weight loss products (shared equipment equals contamination risk)

Let's be clear: "not FDA approved" does not equal "unregulated."

Under DSHEA, FDA does not have authority to approve dietary supplements before they are marketed. That's true. But supplements are still regulated as a category of food.

Regulatory requirements that apply (even without pre-approval):

• Current Good Manufacturing Practices (21 CFR Part 111)
• Manufacturer responsibility for having evidence that products are safe and label claims are truthful
• Post-market enforcement by FDA
• Burden of proof reversal: Once a supplement is marketed, FDA must prove it's not safe to restrict use or remove from market

The legal distinction is disease claims. If you make a disease claim, your product is a drug and requires FDA approval. If you stick to structure/function claims and comply with cGMPs, you're in supplement territory.

Here's where it gets interesting: FDA regulates labels; FTC regulates advertising.

The FTC has primary jurisdiction over supplement advertising under Sections 5 and 12 of the FTC Act. And the FTC has been active.

The Substantiation Standard: "Competent and Reliable Scientific Evidence"

Before you run an ad, you must have adequate substantiation for all objective product claims (express or implied).

What counts as adequate substantiation? Competent and reliable scientific evidence, defined as:

• Tests, analyses, research, studies, or other evidence
• Based on expertise of professionals in relevant area
• Conducted and evaluated objectively
• By persons qualified to do so
• Using procedures generally accepted in the profession
• To yield accurate and reliable results

For health-related benefits, this typically means randomized, controlled human clinical trials (RCTs).

What Doesn't Count

• Animal and in vitro studies: Cannot, standing alone, substantiate health claims
• Surveys of consumer experiences: Insufficient
• Epidemiological/observational studies: Only accepted where experts in the field consider them an acceptable substitute and clinical studies aren't feasible

In December 2022, the FTC issued updated Health Products Compliance Guidance, the first update in nearly 25 years. The message was clear: human clinical trials are required for health-related claims.

Recent FTC Enforcement

As if navigating FDA and FTC requirements wasn't complex enough, states are now creating their own regulations.

New York Age Restrictions

Governor Kathy Hochul signed legislation banning the sale of certain supplements to consumers under age 18. Covered products include those containing:

• Creatine
• Green tea extract
• Raspberry ketone
• Garcinia cambogia
• Green coffee bean extract

Penalties: up to $1,000 per violation.

California's Push for Age Restrictions

In 2022, Governor Gavin Newsom vetoed an age-restriction bill, stating that dietary supplements for weight loss are not considered drugs and that the California Department of Public Health lacked the capability to evaluate every individual weight loss supplement for safety.

But the issue didn't die. In 2024, California's AB 82 advanced through Assembly Health, Justice, and Appropriations Committees despite industry opposition.

Multi-State Trend

Bills to age-restrict weight loss and muscle building supplement sales have been introduced in three states simultaneously. The Council for Responsible Nutrition (CRN) is actively fighting against these restrictions, arguing they create a "dangerous precedent" for consumer access to safe, legal supplements.

Ingredient Bans

California became the first state to ban food and color additives including:

• BVO (brominated vegetable oil)
• Potassium bromate
• Propylparaben
• Red dye 3

New York is proposing to ban these plus azodicarbonamide, butylated hydroxyanisole, and titanium dioxide.

While these bans apply to foods broadly, they impact supplements containing these additives.

The Compliance Nightmare

For national brands and retailers, this growing patchwork means:

• Increased compliance costs
• Operational complexity (tracking state-by-state requirements)
• Need for robust compliance systems
• Ongoing litigation and regulatory uncertainty

Federal Response: The Dietary Supplement Regulatory Uniformity Act

On February 4, 2026, Congressman Nick Langworthy introduced the Dietary Supplement Regulatory Uniformity Act to:

• Reaffirm national oversight of dietary supplement regulation
• Limit emergence of differing state-level requirements
• Maintain consistent, science-based standards under FDA authority

Whether this succeeds in reigning in state fragmentation remains to be seen.

The U.S. is an outlier in how it regulates supplements. Most other major markets require some form of pre-market approval.

Here's the point for brand founders: the direction of travel is toward more regulation, not less.

Senator Durbin's Mandatory Listing Bill

Senator Dick Durbin has introduced the Dietary Supplement Listing Act in 2022, 2024, and most recently on January 15, 2026.

Key provisions:

• Require dietary supplement manufacturers to list products with FDA
• Provide critical information including: Product names, Complete ingredient list, Electronic copy of label, Allergen statements, Health and structure/function claims
• Information made public through electronic database

Previous attempts failed to pass Congress, but momentum is building.

Proponents include:

• Council for Responsible Nutrition (CRN)
• Consumer Federation of America
• United States Pharmacopeia (USP)
• U.S. Public Interest Research Group (U.S. PIRG)
• Ritual (supplement company)

If you're launching a supplement brand today, you're navigating a regulatory landscape that is:

• More complex than most founders realize
• Actively tightening at federal and state levels
• Increasingly enforced (warning letters up 73% in 2025)
• Internationally fragmented (different rules in every major market)

The post-market enforcement model puts the burden on you to have substantiation before making claims. The FTC requires "competent and reliable scientific evidence," typically randomized, controlled human clinical trials.

Most brands don't have this documentation. They rely on supplier studies, ingredient white papers, and marketing copy that crosses into disease claims without realizing it.

The Cost of Non-Compliance

• FTC penalties: Up to $50,120 per violation
• FDA warning letters: Public, permanent records that signal compliance failures
• State-level penalties: $1,000 per violation for age-restriction violations in New York
• Product recalls: If you fail to comply with cGMP or if adulteration is found
• Reputational damage: Once a warning letter is public, competitors and investors see it
• Legal risk: FTC and state authorities can piggyback off FDA enforcement

The Opportunity for Compliant Brands

As regulation tightens, brands with robust compliance documentation and third-party validation will capture market share from brands that cut corners.

Third-party certification is becoming a competitive necessity:

NSF International (NSF/ANSI 173 certification):

• Nation's first independent testing standard for dietary supplements
• Verifies product contains ingredients on label in declared potency
• Tests for contaminants (heavy metals, microbes, pesticides, banned substances)
• Requires annual facility audits and periodic product retesting
• Particularly important for sports nutrition (NSF Certified for Sport program)

USP (US Pharmacopeial Convention) DS Verification Program:

• Independent verification that products meet USP quality standards
• Tests for identity, strength, purity, and quality
• Requires cGMP compliance and facility audits
• USP Verified Mark recognized by healthcare professionals

ConsumerLab.com (CL):

• Independent testing and quality certification
• Publishes pass/fail results publicly (transparency-focused)
• Tests products purchased on open market (not just submitted samples)

Cost and time investment:

• Certification fees: $5,000-$15,000+ annually depending on program and product line
• Application process: 3-6 months
• Ongoing: Annual audits and retesting required

In a 2024 survey, 68% of healthcare professionals said they recommend only third-party certified supplements to patients.

Voluntary and fee-based, these programs are not universal, but they're rapidly becoming the de facto standard for brands serious about quality and compliance.